Americas Morning Research Summary

Investment Ratings - Array Technologies, Inc. (ARRY): Overweight (OW) with a target price change from 18.00 to 11.00 [2] - CACI International: Overweight (OW) with a target price change from 450.00 to 500.00 [2] - Champion Homes, Inc. (SKY): Equal Weight (EW) with a target price change from 68.00 to 85.00 [2] - Endeavour Mining (EDV.L): Overweight (OW) with a target price change from 34.00 to 29.00 [2] - Frontier Group Holdings, Inc. (ULCC): Overweight (OW) with a target price change from 7.00 to 6.00 [2] - Hanesbrands Inc. (HBI): Equal Weight (EW) with a target price change from 5.00 to 6.00 [2] - Hillman Solutions Corp (HLMN): Equal Weight (EW) with a target price change from 9.00 to 10.00 [2] - Insulet (PODD): Equal Weight (EW) with a target price change from 200.00 to 220.00 [2] - Murphy Oil Corporation (MUR): Equal Weight (EW) with a target price change from 54.00 to 46.00 [2] - OGE Energy Corp. (OGE): Equal Weight (EW) with a target price change from 36.00 to 39.00 [2] - OptimizeRx (OPRX): Equal Weight (EW) with a target price change from 15.00 to 11.00 [2] - P10 Inc. (PX): Overweight (OW) with a target price change from 9.50 to 11.00 [2] - Repay Holdings Corp. (RPAY): Overweight (OW) with a target price change from 12.00 to 11.00 [2] - Robinhood Markets, Inc. (HOOD): Underweight (UW) with a target price change from 20.00 to 18.00 [2] - StepStone Group, Inc: Equal Weight (EW) with a target price change from 46.00 to 51.00 [2] - Triumph Group Inc: Overweight (OW) with a target price change from 18.00 to 16.00 [2] - Upstart Holdings Inc. (UPST): Equal Weight (EW) with a target price change from 25.00 to 35.00 [2] Core Insights - The report indicates a notable disconnect between EPS momentum and share price for Endeavour Mining, with expectations of free cash flow (FCF) rising sharply from H2, projecting an 18.1% spot FCF yield in 2025 and a cumulative 2-year cash return yield of 13.8% for 2024 and 2025 [6] - The U.S. healthcare technology and distribution sector is experiencing mixed results, with OptimizeRx facing a revenue miss due to timing delays, while Insulet raised sales and operational margin guidance [22][27] - The U.S. biopharmaceuticals sector is highlighted by strong performances from companies like Eli Lilly, which is breathing confidence into the GLP-1 trade following impressive second-quarter results [25][29] Summary by Category U.S. Autos & Mobility - American Axle & Mfg. (AXL) reported one of the best supplier results of Q2, but leverage issues may mute opportunities for stock performance [31] - Boeing Co. (BA) is tracking the shipping of Dreamlifters, indicating a steady pace of operations [31] U.S. Chemicals - Murphy Oil Corporation (MUR) is guiding down production but ramping up buybacks, indicating a strategic shift in response to market conditions [12] U.S. Healthcare - Insulet's sales beat expectations, and the company raised its sales and operational margin guidance, reflecting positive momentum in the medical supplies and devices sector [22] - OptimizeRx's revenue miss is attributed to timing delays, impacting its stock performance [27] U.S. Biopharmaceuticals - Eli Lilly's strong performance in the GLP-1 market is noted, with significant growth potential anticipated [25][29]